@prefix this: <http://www.tkuhn.ch/bel2nanopub/RArDGxT99qUtiCI1KArF3IwP99d3XhXFWVoqKYEdcZGC0> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RArDGxT99qUtiCI1KArF3IwP99d3XhXFWVoqKYEdcZGC0#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix chebi: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=> .
@prefix RNA: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_33697> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix do: <http://disease-ontology.org/term/DOID:> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   sub:_1 geneProductOf: hgnc:11830 ;
    a RNA: .
  sub:_2 occursIn: do:10534 , species:9606 ;
    rdf:object sub:_1 ;
    rdf:predicate belv:decreases ;
    rdf:subject chebi:49603 ;
    a rdf:Statement .
  sub:assertion rdfs:label "a(CHEBI:lapatinib) -| r(HGNC:TK1)" .
}
sub:provenance {
   beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_4 ;
    pav:version "20131211" .
  sub:_3 prov:value "From our cDNA microarray experiments, we determined that a variety of nucleotide synthesis-related genes, including TS, were downregulated with lapatinib, and this was apparent in HER2-amplified cells (SNU216 gastric cancer cell line). Figure 2. Lapatinib downregulates fluoropyrimidine-target genes. The expressions of representative nucleotide synthesis-related genes [E2F-1, TS, TK1 (thymidine kinase 1), DHFR(dihydrofolate reductase), RRM2 (ribonucleotide reductase M2 polypeptide), DUT (DUTP pyrophosphatase), NME1 (nuclear diphosphate kinase 1)] were reduced as the result of gefitinib or lapatinib treatment in TKI-sensitive cells." ;
    prov:wasQuotedFrom pubmed:19529774 .
  sub:_4 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:19529774 ;
    prov:wasDerivedFrom beldoc: , sub:_3 .
}
sub:pubinfo {
   this: dct:created "2014-07-03T14:33:34.859+02:00"^^xsd:dateTime ;
    pav:createdBy orcid:0000-0001-6818-334X , orcid:0000-0002-1267-0234 .
}